Filtros de búsqueda

Lista de obras de Thomas Prebet

A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study

artículo científico publicado en 2011

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

artículo científico publicado en 2012

A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure

artículo científico publicado en 2014

A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes

artículo científico publicado en 2004

A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse.

artículo científico publicado en 2013

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

artículo científico

A simplified, 96-well-adapted, ATP luminescence-based motility assay

artículo científico publicado en 2009

Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup

artículo científico publicado en 2009

Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies

artículo científico publicado en 2016

Allogeneic hematopoietic SCT and mechanical heart valve: feasibility of reduced toxicity myeloablative conditioning

scientific article published on 22 February 2010

Allogeneic hematopoietic cell transplantation following the use of hypomethylating agents among patients with relapsed or refractory AML: Findings from an international retrospective study.

artículo científico publicado en 2018

An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia ⬇️

artículo científico publicado en 2016

Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia

artículo científico publicado en 2014

Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1.

artículo científico publicado en 2011

Autologous hematopoietic stem cell transplantation for adults with acute myeloid leukemia in complete remission: the Edouard Herriot Hospital experience

artículo científico publicado en 2006

Azacitidine for the treatment of relapsed and refractory AML in older patients.

artículo científico publicado en 2014

Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities

artículo científico publicado en 2015

Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.

artículo científico publicado en 2015

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

artículo científico publicado en 2013

Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

artículo científico publicado en 2013

Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity

artículo científico

Chronic myelomoncytic leukemia: Are we finally solving the identity crisis?

artículo científico publicado en 2016

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.

artículo científico publicado en 2017

Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes

artículo científico publicado en 2017

Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction

scientific article published on 07 August 2012

Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes

artículo científico publicado en 2013

Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes

artículo científico publicado en 2016

Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics

artículo científico publicado en 2014

Concomitant germ-line RUNX1 and acquired ASXL1 mutations in a T-cell acute lymphoblastic leukemia.

artículo científico publicado en 2013

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup

artículo científico publicado en 2014

Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies

artículo científico publicado en 2009

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial.

artículo científico publicado en 2015

Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia

artículo científico publicado en 2015

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

artículo científico publicado en 2008

Emerging treatment options for patients with high-risk myelodysplastic syndrome

scientific article published on 11 November 2020

Evaluation of comorbidity indexes in the outcome of elderly patients treated for acute lymphoblastic leukemia

artículo científico publicado en 2014

Extensive chronic GVHD is associated with donor blood CD34+ cell count after G-CSF mobilization in non-myeloablative allogeneic PBSC transplantation

artículo científico publicado en 2012

Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia

article

High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis

artículo científico publicado en 2020

Histone méthyltransférases

article from 2011

Hypomethylating agent based combinations in higher risk myelodysplastic syndrome

scientific article published on 09 December 2019

Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings

artículo científico publicado en 2016

Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings

artículo científico publicado en 2017

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

artículo científico publicado en 2018

Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine

artículo científico publicado en 2017

Impact of reduced-intensity conditioning allogeneic stem cell transplantation on women's fertility.

artículo científico publicado en 2013

Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study

artículo científico publicado en 2010

Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion

scientific article published on 30 August 2012

Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis.

artículo científico publicado en 2015

Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin.

artículo científico publicado en 2009

Insights into novel emerging epigenetic drugs in myeloid malignancies

artículo científico publicado en 2019

Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

artículo científico publicado en 2011

Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

artículo científico publicado en 2012

Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes

artículo científico publicado en 2016

Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations

artículo científico publicado en 2014

Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States

artículo científico publicado en 2016

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

artículo científico publicado en 2012

Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

artículo científico publicado en 2009

New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities

artículo científico publicado en 2016

Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.

artículo científico publicado en 2012

Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure

artículo científico publicado en 2012

Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia

artículo científico publicado en 2012

Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal Cancer

artículo científico publicado en 2015

PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patients.

artículo científico publicado en 2012

PTK7: a cell polarity receptor with multiple facets

artículo científico publicado en 2011

Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey

artículo científico publicado en 2015

PcG methylation of the HIST1 cluster defines an epigenetic marker of acute myeloid leukemia

artículo científico publicado en 2014

Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone

artículo científico publicado en 2010

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2018

Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia

artículo científico publicado en 2016

Phase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies

artículo científico publicado en 2012

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia

artículo científico publicado en 2016

Planctomycetes DNA in febrile aplastic patients with leukemia, rash, diarrhea, and micronodular pneumonia

artículo científico publicado en 2014

Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation

artículo científico publicado en 2010

Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation

artículo científico publicado en 2014

Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia

artículo científico publicado en 2011

Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system

artículo científico publicado en 2016

Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire

artículo científico publicado en 2008

Presence of a minor Philadelphia-positive clone in young adults with de novo T-cell ALL

artículo científico publicado en 2009

Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation

artículo científico publicado en 2009

Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients

scientific article published on 18 October 2014

Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

artículo científico publicado en 2014

Protein tyrosine kinase 7 has a conserved role in Wnt/β-catenin canonical signalling

artículo científico publicado en 2011

Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies

artículo científico publicado en 2010

Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?

artículo científico publicado en 2014

Secondary Philadelphia chromosome after non-myeloablative peripheral blood stem cell transplantation for a myelodysplastic syndrome in transformation

artículo científico publicado en 2004

Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia

artículo científico publicado en 2016

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial

artículo científico publicado en 2018

The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome

artículo científico publicado en 2010

The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT

artículo científico publicado en 2012

Trends in Clinical Investigation for Myelodysplastic Syndromes

artículo científico publicado en 2016

Tumor cell contamination in ovarian tissue cryopreserved before gonadotoxic treatment: should we systematically exclude ovarian autograft in a cancer survivor?

artículo científico publicado en 2009

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care

artículo científico publicado en 2017

Vorinostat in acute myeloid leukemia and myelodysplastic syndromes

artículo científico publicado en 2010

[Systemic learning planification for medical students during oncology clinical rotation].

artículo científico publicado en 2011

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda